Equities

AtriCure Inc

ATRC:NMQ

AtriCure Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)22.45
  • Today's Change0.14 / 0.63%
  • Shares traded324.13k
  • 1 Year change-53.51%
  • Beta1.4111
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

  • Revenue in USD (TTM)414.60m
  • Net income in USD-37.23m
  • Incorporated2000
  • Employees1.20k
  • Location
    AtriCure Inc7555 Innovation WayMASON 45040United StatesUSA
  • Phone+1 (513) 755-4100
  • Fax+1 (513) 755-4567
  • Websitehttps://www.atricure.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fulgent Genetics Inc287.53m-165.95m650.55m1.18k--0.5751--2.26-5.57-5.579.6437.800.2206--6.01242,846.30-13.2916.70-14.1618.3737.4767.89-60.2529.06----0.00140.00-53.2768.41-217.03--57.08--
Orthopediatrics Corp161.83m-21.97m775.15m247.00--2.07--4.79-0.9647-0.96477.1115.740.37480.42475.13655,178.10-5.09-5.40-5.62-5.9374.0775.09-13.58-15.921.99--0.0271--21.6220.91-1,767.25--28.29--
Cytek Biosciences Inc200.79m-11.51m782.39m637.00--1.99--3.90-0.0856-0.08561.502.990.3951.444.30297,020.70-2.26---2.54--55.48---5.73--6.01--0.0086--17.67---571.58------
Embecta Corp1.13bn70.20m803.35m2.20k11.45--7.590.70941.221.2219.62-13.350.942.5115.86514,772.705.83--8.06--65.57--6.20--1.791.511.89---0.7703---68.52------
Atrion Corp176.67m18.72m831.40m712.0044.423.4424.274.7110.6310.63100.32137.460.67941.567.93248,127.807.2011.967.6312.6233.7741.9910.6019.053.06--0.0042.42-7.732.12-44.55-10.744.9811.27
Silk Road Medical Inc185.49m-53.42m896.95m474.00--6.09--4.84-1.37-1.374.763.730.72472.087.87391,322.80-20.87-29.02-22.75-32.9873.3172.91-28.80-46.849.62--0.34--27.7738.66-1.33---7.92--
Avanos Medical Inc680.10m-1.60m932.77m3.77k--0.762321.301.37-0.0315-1.3314.6226.650.40051.625.48180,350.00-0.0942-0.6527-0.1055-0.733856.3354.45-0.2353-1.601.474.850.1257---1.580.6357-146.05---18.37--
Artivion Inc368.21m-9.58m993.70m1.50k--3.3772.932.70-0.2615-0.26158.647.070.47791.645.37245,470.70-1.25-2.20-1.33-2.3664.7565.51-2.61-5.344.262.260.5176--12.826.14-60.09--5.13--
BioLife Solutions Inc137.30m-62.93m1.00bn409.00--2.99--7.32-1.43-1.433.107.300.32382.175.61335,687.00-14.84-13.76-16.52-15.0432.9736.76-45.84-42.991.77-32.080.0717---11.4348.6552.49--86.35--
AtriCure Inc414.60m-37.23m1.08bn1.20k--2.37--2.60-0.8005-0.80058.929.430.70591.708.21345,501.70-6.34-3.72-7.08-4.1075.2674.36-8.98-7.642.83-10.270.1212--20.8414.6434.49--46.56--
Coretag Inc0.00-34.52k1.13bn0.00---------0.3806-0.38060.00-0.98010.00-------3,303.35--------------------------10.95------
MiMedx Group Inc334.51m71.52m1.18bn895.0021.237.5814.823.530.37670.33932.151.061.722.826.58373,754.2041.80-4.1453.13-5.9083.5083.6124.36-2.702.719.000.111--20.03-2.19310.29---26.47--
Adapthealth Corp3.25bn-695.41m1.32bn10.70k--0.9012--0.4056-5.18-5.1824.2710.970.663721.668.30303,555.90-14.15-4.34-15.82-4.8918.4518.28-21.32-6.471.112.080.6025--7.73---1,169.99------
Owens & Minor, Inc.10.42bn-38.77m1.38bn13.70k--1.545.470.1321-0.5099-0.5099136.9811.711.986.7914.60760,861.20-0.73721.32-1.112.0720.7516.48-0.37190.56140.56482.190.70650.7983.801.87-284.47--25.91--
Establishment Labs Holdings Inc155.79m-82.76m1.49bn781.00--26.07--9.54-3.15-3.155.912.070.60950.91913.39171,579.30-32.38-33.22-39.25-41.1265.0164.73-53.12-43.192.73-21.300.7715--2.1321.96-4.38--69.16--
Data as of May 21 2024. Currency figures normalised to AtriCure Inc's reporting currency: US Dollar USD

Institutional shareholders

47.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20244.63m9.58%
AllianceBernstein LPas of 31 Mar 20243.65m7.55%
BlackRock Fund Advisorsas of 31 Mar 20243.47m7.17%
Champlain Investment Partners LLCas of 31 Mar 20242.68m5.54%
Fidelity Management & Research Co. LLCas of 31 Mar 20241.77m3.67%
Wellington Management Co. LLPas of 31 Mar 20241.64m3.39%
Macquarie Investment Management Business Trustas of 31 Mar 20241.41m2.92%
First Light Asset Management LLCas of 31 Mar 20241.38m2.86%
SSgA Funds Management, Inc.as of 31 Mar 20241.19m2.45%
Geode Capital Management LLCas of 31 Mar 20241.06m2.19%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.